- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00475735
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Incomplete Block, Two-period, Crossover Clinical Trial to Study the Safety and Efficacy of MK0249, 10 mg, for Adult Patients, Ages 18 to 55, With Attention Deficit Hyperactivity Disorder (ADHD)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is between 18 and 55 years of age (inclusive)
- Patient is an adult with a current DSM-IV diagnosis of ADHD of inattentive or combined subtype, as assessed via a structured interview using the ACDS and AISRS
- Females of child-bearing potential must use acceptable methods of birth control during the study and for 1 month post-therapy
Exclusion Criteria:
- Patient has a history of a neurological disorder resulting in ongoing impairment
- Patient has a lifetime history of a psychotic disorder, bipolar disorder, or post-traumatic stress disorder
- Patient has evidence of ongoing depression
- Patient is sensitive or allergic to methylphenidate
- Patient has glaucoma
- Patient has a previous history of narrowing or blockage of the GI tract
- Patient has a history of a sleep disorder (e.g., insomnia, sleep apnea, nightmares, or night terrors) within 6 months prior to screening
- Patient has a history of a cardiovascular disorder within 6 months prior to screening
- Patient has moderate or severe persistent asthma
- Patient has a history of substance abuse or dependence not in sustained full remission for at least one year according to DSM-IV
- Patient has taken part in a research study within the past 30 days of signing informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MK-0249
Total time in the study will be ~10 weeks.
|
MK-0249, 10 mg per day was taken orally daily.
If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
|
Active Comparator: Concerta
Total time in the study will be ~10 weeks.
|
Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period.
If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day.
Concerta was taken orally once daily.
Other Names:
|
Placebo Comparator: Placebo
Total time in the study will be ~10 weeks.
|
For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules).
For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided.
Each patient was to dose with tablets and capsules, either active or placebo.
Placebo was taken orally once daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in the Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale (AISRS) Total Score After 4 Weeks of Treatment
Time Frame: after 4 weeks of treatment
|
The AISRS total score consists of 18 items from the original Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) which were derived based on Diagnostic and Statistical Manual-4 (DSM-IV) criteria for ADHD.
The ADHD-RS include 9 items that address symptoms of inattention and 9 items that address symptoms of impulsivity and hyperactivity.
Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54.
A higher score corresponds to a worse severity of ADHD.
|
after 4 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in the AISRS Inattentive Subscale Score After 4 Weeks of Treatment
Time Frame: after 4 weeks of treatment
|
The AISRS inattentive subscale score consists of 9 items from the original ADHD-RS which address inattention. Each item is rated from 0 to 3. The AISRS inattentive subscale score can range from 0 to 27. A higher score corresponds to a worse severity of ADHD inattentiveness. Data not reported due to failure of primary hypothesis and program termination. |
after 4 weeks of treatment
|
>/= 30% AISRS Total Score Responder Rate After 4 Weeks of Treatment;
Time Frame: after 4 weeks of treatment
|
The AISRS total score consists of 18 items from the original ADHD-RS which were derived based on DSM-IV criteria for ADHD. The ADHD-RS include 9 items that address symptoms of inattention and 9 items that address symptoms of impulsivity and hyperactivity. Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54. A higher score corresponds to a worse severity of ADHD. Data not reported due to failure of primary hypothesis and program termination. |
after 4 weeks of treatment
|
>/=1-point Improvement in the CGI-S Score
Time Frame: 4 weeks of treatment
|
The Clinical Global Impression - Severity of Illness Scale (CGI-S) is administered by a trained investigator who rates the severity of a patient's illness at the time of assessment, relative to the investigator's past experience with patients who have an ADHD diagnosis. The scores range from 1 to 7. Higher numbers correspond to more severe illness. Data not reported due to failure of primary hypothesis and program termination. |
4 weeks of treatment
|
Mean Change From Baseline in the AISRS Hyperactive/Impulsive Subscale Score
Time Frame: 4 weeks of treatment
|
The Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale (AISRS) hyperactive/impulsive subscale score consists of 9 items from the original Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) which address hyperactivity and impulsivity. Each item is rated from 0 to 3. The AISRS hyperactive/impulsive subscale score can range from 0 to 27. A higher score corresponds to a worse severity of ADHD hyperactivity/impulsivity. Data not reported due to failure of primary hypothesis and program termination |
4 weeks of treatment
|
Mean Change From Baseline in the Conners' Adult ADHD Rating Scale - Observer Screening Version (CAARS-O:SV) Total ADHD Symptom Score.
Time Frame: 4 weeks of treatment
|
Conners' Adult ADHD Rating Scale - Observer Screening version (CAARS-O: SV) evaluates DSM-IV-oriented inattention, impulsivity and hyperactivity as well as measures of self-concept. It is a 30-item scale administered by a trained investigator or rater with "cue" questions. Each item is scored from 0 to 3 with higher scores corresponding to worse symptoms. The total score can range from 0 to 90. Data not reported due to failure of primary hypothesis and program termination. |
4 weeks of treatment
|
Mean Change From Baseline in the Clinical Global Impressions-severity of Illness Scale(CGI-S) Score
Time Frame: 4 weeks of treatment
|
The Clinical Global Impression - Severity of Illness Scale (CGI-S) is administered by a trained investigator who rates the severity of a patient's illness at the time of assessment, relative to the investigator's past experience with patients who have an ADHD diagnosis. The scores range from 1 to 7. Higher numbers correspond to more severe illness. Data not reported due to failure of primary hypothesis and program termination. |
4 weeks of treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline AISRS
Time Frame: Baseline
|
Baseline values for all treatment groups are equal because the constrained longitudinal data analysis (cLDA) model was used (Liang and Zeger, 2000, Sankhyā: The Indian Journal of Statistics, Series B 62, 134-148). |
Baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Methylphenidate
Other Study ID Numbers
- 0249-018
- 2007_519
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention-Deficit/Hyperactivity Disorder (ADHD)
-
Children's National Research InstituteRecruitingADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - Impulsive | Attention-Deficit Disorder in Adolescence | Attention-Deficit Hyperactivity...United States
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Cingulate TherapeuticsPremier Research Group plcActive, not recruitingADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ironshore Pharmaceuticals and Development, IncCompletedAttention-Deficit Hyperactivity Disorder (ADHD)United States
-
Massachusetts General HospitalShireCompletedAttention Deficit/Hyperactivity Disorder(ADHD)United States
-
Medical University of South CarolinaShireCompletedAdult Attention Deficit Hyperactivity Disorder (ADHD)United States
-
Sheba Medical CenterCompletedADHD Predominantly Inattentive Type | Attention Deficit/Hyperactivity Disorder Combined Type | ADHD Predominantly Hyperactivity Type | ADHD-not Other SpecifiedIsrael
-
Cingulate TherapeuticsRho, Inc.CompletedADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder CombinedUnited States
-
Tris Pharma, Inc.Massachusetts General Hospital; Massachusetts Institute of TechnologyCompleted
-
Karolinska InstitutetRegion StockholmCompleted
Clinical Trials on MK0249
-
Merck Sharp & Dohme LLCCompletedAlzheimer's Disease
-
Merck Sharp & Dohme LLCCompletedParanoid Schizophrenia
-
Merck Sharp & Dohme LLCTerminatedSleep Apnea, Obstructive | Hypopnea Syndrome | Excessive Daytime Sleepiness